Strategic Advantages | Discover the benefits of Rezolute's Orphan Drug Designation for ersodetug, including tax credits, fee exemptions, and potential market exclusivity |
Market Potential | Learn how Rezolute's stock surged 27.65% on positive trial news, with analyst price targets ranging from $9 to $15, suggesting significant upside potential |
Financial Strength | Delve into Rezolute's robust financial position, boasting $105 million in cash and a current ratio of 8.43, providing ample runway for drug development |
Clinical Milestones | Explore Rezolute's progress in Phase 3 trials for ersodetug, targeting congenital and tumor-induced hyperinsulinism, with key interim results expected soon |
Metrics to compare | RZLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRZLTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −5.8x | −0.2x | |
PEG Ratio | −0.30 | −0.04 | 0.00 | |
Price / Book | 5.1x | 3.9x | 2.6x | |
Price / LTM Sales | - | 17.6x | 2.8x | |
Upside (Analyst Target) | 144.6% | 123.0% | 62.3% | |
Fair Value Upside | Unlock | 13.8% | 8.2% | Unlock |
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.